



Relevant Disclosures

- Consultant / Grant Support: Allergan, Apellis, Genentech / Roche, Novartis, Regeneron, REGENXBIO, Adverum, Clearside Biomedical, Opthea, Samsung, Santen, Bayer, Senju, Zeiss, Heidelberg, OHR, BioTime, Gemini, Chengdu Kanghong Biotechnology, Optos, Kodiak Sciences, Johnson & Johnson
- · Co-patent holder on OPTOS de-warping algorithms
- OPTOS provided support for DAVE

DMB had full control of the presentation








Clinical Importance of the Peripheral Retina


- •Retinal Vascular Diseases
- •Diabetic Retinopathy •Surgical Diseases
- •Uveitis & Tumors









































Clinical Importance of the Peripheral Retina


- •Retinal Vascular Diseases
- Diabetic Retinopathy
 Surgical Diseases
 Uveitis & Tumors































































































Baseline Patient Demographics				
	Anti-VEGF only	Anti-VEGF + TRP	Total	
% OD	35% (7/20)	55% (11/20)	45% (18/40)	
Mean Age (range)	55 (44-73)	56 (31 - 73)	55 (31 - 73)	
% Female	20% (4/20)	25% (5/20)	24% (7/29)	
Mean HbAIC (range)	8.8 (5.9 - 12.9)	8 (5.9 - 12.8)	8.6 (5.9 - 12.9)	
Mean DM Diagnisis Year (range)	2002 (1982 - 2012)	2001 (1980 - 2012)	2001 (1980 - 2012)	
Mean DME Diagnosis Year (range)	2012 (2008 - 2014)	2012 (2010 - 2014)	2012 (2008 - 2014)	
Mean ETDRS BCVA (range) Snellen equivalent	59.1(23 – 75) 20/63 (20/400 – 20/32)	60.1 (37 – 76) 20/63 (20/200 – 20/32)	59.6 (23 – 76) 20/63 (20/400 – 20/32)	
Mean CRT (range)	571 μm (262 – 1034)	488 µm (273 – 946)	530 µm (262 – 1034)	

	Compliance					
Cohort	# Patients Complet ed M36	# Patient s Droppe d	# Patient s Analyze d (LOCF)	# Possibl e Visits	# Missed Visits	% Visits Missed
Anti-VEGF only	16	4	18	694	71	10%
Anti-VEGF + TRP	18	2	19	743	70	9%













Anti-VEGF only (n=9) 10291 degrees ² 10076 degrees ² -2% Anti-VEGF + TRP (n=8) 9826 degrees ² 8102 degrees ² -18%
Anti-VEGE + TRP (n=8) 9876 degrees2 8102 degrees2 -18%
125. 11. (i. 6) 7525 degrees 0.02 degrees 10/0


Adverse Events				
	Monotherapy Cohort	Combination Therapy Cohort		
Ocular Adverse Events				
Vitreous Hemorrhage	2 (10%)	2 (10%)		
Neovascularization elsewhere	4 (20%)	0 (0%)		
Neovascularization of the disc	2 (10%)	0 (0%)		
Neovascularization of the iris	2 (10%)	0 (0%)		
Worsening glaucoma	3 (15%)	0 (0%)		
Worsening cataract	3 (15%)	6 (30%)		
Posterior vitreous detachment	4 (20%)	5 (25%)		
Epiretinal membrane	I (5%)	3 (15%)		
Hyphema	2 (10%)	0 (0%)		
Dilated pupil	0 (0%)	I (5%)		
Notable Serious Adverse Events				
Neovascular glaucoma	2 (10%)	0 (0%)		
Vitreous hemorrhage with acute vision loss	0 (0%)	I (5%)		
Sepsis	1* (5%)	1* (5%)		
Systolic heart failure	I* (5%)	1* (5%)		
Atrial flutter	I* (5%)	I* (5%)		
Coronary artery disease	0 (0%)	I (5%)		
Pneumonia	2* (10%)	I* (5%)		
Osteomyelitis	3* (15%)	1* (5%)		
Cellulitis	2 (10%)	I (5%)		
Worsening renal failure	3 (15%)	4 (20%)		






































































Clinical Importance of the Peripheral Retina


- •Retinal Vascular Diseases
- •Diabetic Retinopathy
 •Surgical Diseases
- •Uveitis & Tumors


































Principles of OCT Angiography Motion Contrast Detection of Flow Structure : OCT Flow : OCT Angiography • Detects blood cell motion contrast • Cross-sectional images acquired rapidly and repeatedly from the same location on the retina • The flow is seen as the difference between two subsequent image


Example of using motion contrast to highlight the flowing water in this water faucet video


frames: Flow = Frame #1 – Frame #2


- Non-invasive way of imaging blood vessels
- Allows visualization of the deep choroidal plexus
- Allows information in 3 seconds
- Used for: CNV, RVO, Diabetes, Arterial occlusion, Uveitis, AMPPE, Polypoidal disease,













Superficial vascular plexus is clearly visible

 Valuable for vascular diseases involving the macula




Deep capillary plexus is clearly visible


- Important for outer retinal vascular diseases
- Helps to analyze deep capillary ischemia





Choriocapillaris is visible

- Helpful to highlight the tightly packed network under the macula
- May help to show impact of treatments to RPE













A TALE OF TWO RETINAS...


David M Brown MD Retina Consultants of Houston, Houston Methodist Hospital, TX





















CNV in Central Serous

- A.=IVFA
- B.=OCT-A
- Using automateddepth imagingC.=ICGD.=OCT-A




Type 1 NV Tangled Network

Type 1 NV Sea fan-like blood vessels with large feeder vessels and large caliper vessels





Type 1 NV Cartwheel network





Type 2 NV FA vs. ICGA vs. OCT Angiography



FA





ICGA





AngioVue


Prof. Federico Ricci, Tor Vergata University, Rome, Italy














































Diabetic Retinopathy


· OCT angiography can clearly visualize microaneurysms and retinal non-perfused areas and enables closer observation of each layer of the retinal capillaries



OCT-A in Diabetic Retinopathy



OCT-A in **Diabetic** Retinopathy



Diabetes



- Capillary non-perfusion Microaneurysms
- Microaneurysms' lumen obliteration



Diabetes: Neovascularization (proliferative diabetic retinopathy)


Diabetes





- Capillary non-perfusion Microaneurysms


 - Microaneurysms' lumen obliteration
 - Diabetes: Neovascularization (proliferative diabetic retinopathy)
















Middle Maculopathy PAMM



















Case


VA: OD: 20/20 OS: 20/60


Comments: Interesting case of 25yo with APMPPE. OCTA OD particularly dramatic, showing decreased choriocap flow in area of lesions that then improves over time as lesions resolve. She was treated with oral Pred. VA improved to 20/20 ou as of last visit.



































































- In the future the OCT-A may help us follow, aid in diagnosis, and change our treatment paradigms for patients with CNV
 The OCT-A aids in determining where the pathology is occurring non invasively
 The OCT-A may help guide drug development

